Regsiter now for a personalized educational experience.
Already a member? Log In
By linking your Doximity account with UPMC Physician Resources, you acknowledge that:
Forgot your password? Enter the email address you used to create your account to initiate a password reset.
University of Pittsburgh Physicians Department of Neurological Surgery Hillman Cancer Center 5150 Centre Ave. 2nd Floor Pittsburgh, PA 15232 Office Phone: (412) 647-7614
Johnathan Engh, MD, joined the University of Pittsburgh Department of Neurological Surgery in 2008 as an assistant professor and director of the Neuroendoport Surgery Program after completing the department’s seven-year residency program. He subsequently built this program into a national referral center for deep-seated brain tumors and colloid cysts.
Dr. Engh became the director of adult neurosurgical oncology at the University of Pittsburgh in 2014. He was promoted to associate professor in 2014 and he received a secondary appointment as associate professor in the Department of Radiation Oncology in 2016.
Dr. Engh’s primary medical staff appointments are at UPMC Shadyside and UPMC Presbyterian Hospitals but he also has consulting privileges at Children’s Hospital of Pittsburgh of UPMC, Magee Women’s Hospital of UPMC and UPMC Passavant. In addition, he provides outpatient consulting services via telemedicine at UPMC Bedford and UPMC Northwest.
Originally from northern Virginia, Dr. Engh is a graduate of Duke University and the University of Virginia Medical School.
Dr. Engh’s clinical focus is on neurosurgical oncology, especially minimally invasive operations for central nervous system tumors and intraventricular lesions. From a research perspective, his major interests are the development of minimally invasive tools for cranial surgery and surgical trials for the treatment of brain tumors.
See also: Dr. Engh Receives ACES Award
CNS tumors, minimally invasive surgery, neurosurgical technology and innovation.
American Board of Neurological Surgery
Children’s Hospital of Pittsburgh of UPMC
Magee-Womens Hospital of UPMC
Allegheny County Medical Society
Alpha Omega Alpha
American Association of Neurological Surgeons
Congress of Neurological Surgeons
Pennsylvania Medical Society
Society of Neuro-Oncology
University of Pittsburgh Cancer Institute
BS, Biology and Religion, Duke University, 1997
MD, University of Virginia, 2001
Residency, Neurological Surgery, University of Pittsburgh, 2008
Fellowship, Neurosurgical Oncology, University of Pittsburgh, 2007
America’s Best Doctors, 2011-16
Pittsburgh’s Best Doctors, 2012-2016
UPMC ACES Award, 2014
Holt DE, Gill BS, Clump DA, Leeman JE, Burton SA, Amankulor NM, Engh JA, Heron DE. Tumor bed radiosurgery following resection and prior stereotactic radiosurgery for locally persistent brain metastasis. Front Oncol 8;5:84, 2015.
Ling D, Vargo JA, Wegner RE, Flickinger JC, Burton S, Engh J, Amankulor N, Quinn AE, Ozhasoglu C, Heron DE. Post-operative stereotactic radiosurgery to the resection cavity for large brain metastases: clinical outcomes, predictors of intracranial failure, and implications for optimal patient selection. Neurosurgery 76(2):150-7, 2015.
Weiner GM, Chivukula S, Chen CJ, Ding D, Engh JA, Amankulor N. Ommaya reservoir with ventricular catheter placement for chemotherapy with frameless and pinless electromagnetic surgical neuronavigation. Clin Neurol Neurosurg 130:61-6, 2015.
Okada H, Butterfield LH, Hamilton RL, Hoji A, Sakaki M, Ahn BJ, Kohanbash G, Drappatz J, Engh J, Amankulor N, Lively MO, Chan MD, Salazar AM, Shaw EG, Potter DM, Lieberman FS. Induction of robust type-1 CD8+ T-cell responses in WHO grade II low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin Cancer Res 15;21(2):286-94, 2015
Chivukula S, Engh J. A Singular Case of Intracranial Sinus Histiocytosis “without” Massive Lymphadenopathy: Isolated Rosai-Dorfman Disease of the Hypothalamus. J Neurol Surg A Cent Eur Neurosurg 76(3):244-8, 2015.
Abhinav K, Pathak S, Richardson RM, Engh J, Gardner P, Yeh FC, Friedlander RM, Fernandez-Miranda JC. Application of High Definition Fiber Tractography (HDFT) in Management of Supratentorial Cavernous Malformations: a combined qualitative and quantitative approach. Neurosurgery 74(6):668-81, 2014.
Luther N, Kondziolka D, Kano H, Mousavi SH, Engh JA, Niranjan A, Flickinger JC, Lunsford LD. Predicting Tumor Control After Resection Bed Radiosurgery of Brain Metastases. Neurosurgery 73(6):1001-6, 2013.
Thirumala P, Lai D, Engh J, Habeych M, Crammond D, Balzer J. Predictive Value of Somatosensory Evoked Potential Monitoring during Resection of Intraparenchymal and Intraventricular Tumors Using an Endoscopic Port. J Clin Neurol 9(4):244-251, 2013.
Faraji AH, Engh JA, Horowitz M, Lunsford LD, Park DM. Multiple discrete aneurysmal subarachnoid hemorrhages during multimodality management of a hypothalamic glioma-case report. Clinical Neurology and Neurosurgery 115(5):632-635, 2013.
McLaughlin N, Prevedello DM, Engh J, Kelly DF, Kassam AB. Endoneurosurgical resection of intraventricular and intraparenchymal lesions using the port technique. World Neurosurg 79(2 Suppl):S18.e1-8, 2013.
A complete list of Dr. Engh's publications can be reviewed through the National Library of Medicine's publication database.
Dr. Engh’s current research efforts have been focused on the development of dilatable brain access ports for tumor surgery. Over the spring and summer of 2016, with the backing of the innovative practice committee of the University of Pittsburgh, Dr. Engh has implemented a dilatable balloon catheter to achieve access for minimally invasive endoscopic port surgery in a select number of patients. This human research is paired with animal research investigating the effects of various methods of access into the brain.
In addition, numerous clinical trials for patients with brain tumors are overseen by Dr. Engh at the Hillman Cancer Center. Exciting initiatives include a retroviral vector for tumor treatment, fluorescent dye for maximizing brain tumor resection, and a complex tumor banking initiative for the development of patient-specific therapies for both primary and metastatic brain tumors.